Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
暂无分享,去创建一个
A. Lluch | P. Eroles | B. Bermejo | M. T. Martínez | C. Hernando | O. Burgués | I. Garrido-Cano | A. Lameirinhas | Sandra Torres-Ruiz | Marta Tapia | Cristina Tebar-Sánchez | A. Ágreda-Roca
[1] R. Bianco,et al. The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer , 2023, Frontiers in oncology.
[2] Jianguo Feng,et al. Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer , 2023, NPJ breast cancer.
[3] Claire E. Tocheny,et al. The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target , 2022, Life.
[4] S. Swain,et al. Targeting HER2-positive breast cancer: advances and future directions , 2022, Nature Reviews Drug Discovery.
[5] Hongjian Yang,et al. Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies , 2022, Frontiers in Pharmacology.
[6] S. Tolaney,et al. Overcoming Resistance to HER2-Directed Therapies in Breast Cancer , 2022, Cancers.
[7] H. Rugo,et al. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer , 2022, ESMO open.
[8] A. Lucci,et al. Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers , 2022, International journal of molecular sciences.
[9] Sung-Bae Kim,et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.
[10] Y. Kong,et al. N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer , 2022, Nature Communications.
[11] F. Rojo,et al. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer , 2022, Science advances.
[12] P. Chu,et al. Current and Developing Liquid Biopsy Techniques for Breast Cancer , 2022, Cancers.
[13] Min Hwan Kim,et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. , 2022, The New England journal of medicine.
[14] J. Huober,et al. New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development , 2022, Exploration of targeted anti-tumor therapy.
[15] Safi Ullah,et al. Breast Cancer; Discovery of Novel Diagnostic Biomarkers, Drug Resistance, and Therapeutic Implications , 2022, Frontiers in Molecular Biosciences.
[16] E. Dı́az-Rodrı́guez,et al. Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs , 2021, Cancers.
[17] M. Miączyńska,et al. Bemcentinib and gilteritinib inhibit cell growth and impair the endo-lysosomal and autophagy systems in an AXL-independent manner. , 2021, Molecular cancer research : MCR.
[18] A. Bardia,et al. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies , 2021, CA: a cancer journal for clinicians.
[19] Xin Hu,et al. Large‐scale genomic sequencing reveals adaptive opportunity of targeting mutated‐PI3Kα in early and advanced HER2‐positive breast cancer , 2021, Clinical and translational medicine.
[20] A. Prat,et al. Current and Future Management of HER2-Positive Metastatic Breast Cancer. , 2021, JCO oncology practice.
[21] A. Lluch,et al. Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer , 2021, Cancers.
[22] S. Swain,et al. HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now , 2021, NPJ breast cancer.
[23] E. Winer,et al. Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. , 2021, Cancer discovery.
[24] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[25] S. Tolaney,et al. HER2-positive metastatic breast cancer: a comprehensive review. , 2021, Clinical advances in hematology & oncology : H&O.
[26] S. Shchegrova,et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] Sung-Bae Kim,et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. , 2020, The Lancet. Oncology.
[28] P. Nuciforo,et al. Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial , 2020, Clinical Cancer Research.
[29] F. Nuzzo,et al. Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors , 2020, International journal of molecular sciences.
[30] W. den Besten,et al. Prospecting for molecular glues , 2020, Nature Chemical Biology.
[31] Sung-Bae Kim,et al. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] B. Sun,et al. The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2 in vitro and in Immune Competent Mice , 2020, Frontiers in Oncology.
[33] R. Bose,et al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] Sung-Bae Kim,et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. , 2020, The Lancet. Oncology.
[35] Edward W. Tate,et al. Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4 , 2020, ACS chemical biology.
[36] A. Forero-Torres,et al. Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models , 2020, Molecular Cancer Therapeutics.
[37] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. , 2020, The Lancet. Oncology.
[38] J. Arribas,et al. The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1 , 2020, Cancers.
[39] A. Thor,et al. Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem , 2020, Cancer drug resistance.
[40] A. Pandiella,et al. HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates , 2020, Breast Cancer Research.
[41] R. Greil,et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. , 2019, The New England journal of medicine.
[42] Sung-Bae Kim,et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. , 2019, The New England journal of medicine.
[43] E. D. de Vries,et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. , 2019, The Lancet. Oncology.
[44] L. Matis,et al. Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343 , 2019, Clinical Cancer Research.
[45] T. Agatsuma,et al. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. , 2019, Chemical & pharmaceutical bulletin.
[46] A. Galey,et al. Abstract P6-17-13: ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers , 2019, Poster Session Abstracts.
[47] S. Hurvitz,et al. Abstract P6-17-11: The small molecule inhibitor of HER2, tucatinib, has potent and highly selective activity in preclinical modes of HER2-driven cancer , 2019, Poster Session Abstracts.
[48] P. Fasching,et al. Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer , 2019, The New England journal of medicine.
[49] V. Gadi,et al. Dasatinib in breast cancer: Src-ing for response in all the wrong kinases. , 2018, Annals of translational medicine.
[50] R. Bartsch,et al. ASCO 2018: highlights in HER2-positive metastatic breast cancer , 2018, memo - Magazine of European Medical Oncology.
[51] Sung-Bae Kim,et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.
[52] Sung-Bae Kim,et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. , 2017, The Lancet. Oncology.
[53] S. Ikeda,et al. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors. , 2016, JAMA oncology.
[54] J. Diehl,et al. Cyclin D1, cancer progression, and opportunities in cancer treatment , 2016, Journal of Molecular Medicine.
[55] G. Kallergi,et al. Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients , 2015, Breast Cancer Research.
[56] Qingyuan Zhang,et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. , 2015, The Lancet. Oncology.
[57] R. Nahta,et al. Insulin-Like Growth Factor-1 Receptor Signaling Increases the Invasive Potential of Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer Cells via Src-Focal Adhesion Kinase and Forkhead Box Protein M1 , 2015, Molecular Pharmacology.
[58] M. Piccart,et al. High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab , 2014, Clinical Cancer Research.
[59] E. Lerma,et al. Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma , 2014, British Journal of Cancer.
[60] Li Ding,et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.
[61] R. Tripaldi,et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth , 2013, Oncogene.
[62] R. Nahta. Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer , 2012, ISRN oncology.
[63] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[64] J. Baselga,et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] W. Franklin,et al. Mer or Axl Receptor Tyrosine Kinase Inhibition Promotes Apoptosis, Blocks Growth, and Enhances Chemosensitivity of Human Non-Small Cell Lung Cancer , 2012, Oncogene.
[66] Jae Cheol Lee,et al. Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.
[67] S. Loi,et al. Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy , 2011, Proceedings of the National Academy of Sciences.
[68] Hua Guo,et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways , 2011, Nature Medicine.
[69] E. Knudsen,et al. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure , 2010, Oncogene.
[70] Y. Hitoshi,et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. , 2010, Cancer research.
[71] P. Pohlmann,et al. Resistance to Trastuzumab in Breast Cancer , 2009, Clinical Cancer Research.
[72] J. Dering,et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.
[73] R. Salgia,et al. The MET axis as a therapeutic target. , 2009, Update on cancer therapeutics.
[74] M. Berger,et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.
[75] G. Hortobagyi,et al. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer , 2006, Nature Clinical Practice Oncology.
[76] E. Lengyel,et al. C‐Met overexpression in node‐positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu , 2005, International journal of cancer.
[77] Timothy J. Yeatman,et al. A renaissance for SRC , 2004, Nature Reviews Cancer.
[78] B. Leyland-Jones,et al. A tipping-point for apoptosis following dual inhibition of HER2 signaling network by T-DM1 plus GDC-0980 maximizes anti-tumor efficacy. , 2021, American journal of cancer research.
[79] U. Martens. Small Molecules in Oncology , 2018, Recent Results in Cancer Research.
[80] M. Clynes,et al. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[81] H. Earp,et al. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. , 2008, Advances in cancer research.
[82] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.